Novo’s Obesity Franchise On Track For YE22 But Diabetes Pipeline Steals Show During Q3
As Lilly’s Rival Beats Expectations
Executive Summary
Updates regarding Novo Nordisk’s obesity product Wegovy dominated the Danish firm’s Q3 results call, but observers were also keen to hear of diabetes R&D milestones as Eli Lilly’s competitor Mounjaro entered the market with a bang.
You may also be interested in...
Wegovy Demand Busts Through Novo Nordisk’s Expanded Capacity
Novo Nordisk said it would temporarily reduce production of the lower starting dose of Wegovy even as a second contract manufacturer has come online in April.
Five-Plus-Five Equals A Focus On Execution At Lilly In 2023
Executives told Scrip the company is ready to move five programs into Phase III and launch five products this year, including an obesity indication for Mounjaro, but one drug has since received a CRL.
Novo Targets Teens With Wegovy As It Heads Off Lilly Mounjaro Threat
The Danish firm’s GLP-1 receptor agonist triggered significant weight loss in a Phase III trial in obese teenagers, sparking filing plans that could strengthen the product’s market share even as rival Eli Lilly mounts a threat with Mounjaro.